Scientists investigate why some thyroid cancers resist radioactive iodine
NCT ID NCT07314255
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study examines why some papillary thyroid cancers respond well to radioactive iodine-131 therapy while others do not. Researchers will compare tissue samples and PET scans from 60 patients who have already had treatment, focusing on a protein called Trop2. The goal is to understand factors that influence treatment resistance and survival, which may help guide future therapies.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for I-131 are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Jiangxi Cancer Hospital
Nanchang, Jiangxi, 330000, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.